Trial Profile
A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Vercirnon (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SHIELD-2
- Sponsors GlaxoSmithKline; GSK
- 22 Dec 2021 This trial has been completed in Belgium (Global end date: 23 Oct 2013).
- 06 Feb 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 10 Jan 2014 Planned End Date changed from 1 Apr 2015 to 1 Sep 2013 as reported by ClinicalTrials.gov record.